Literature DB >> 1834329

Predominance of the metastatic phenotype in somatic cell hybrids of the K-1735 murine melanoma.

A H Staroselsky1, S Pathak, Y Chernajovsky, S L Tucker, I J Fidler.   

Abstract

The purpose of these studies was to determine whether the metastatic phenotype will dominate when metastatic and nonmetastatic clones of the K-1735 mouse melanoma are hybridized by somatic cell fusion. Three nonmetastatic and three metastatic clones were transfected with DNA from plasmids pSV2neo or pSV2hygro, which confer resistance to the drugs neomycin or hygromycin, respectively. The metastatic properties of the six clones were not altered by these transfections. The tumorigenicity and metastatic capacity of cell hybrids formed by somatic cell fusion of nonmetastatic and metastatic clones were examined. To do so, near-tetraploid hybrids containing a nearly complete chromosomal complement from both parental cells were injected i.v. into syngeneic mice, and the number of metastatic nodules in the lung was determined at 45 days or when the mice became moribund. Seven of nine hybrids produced from the fusion of metastatic and nonmetastatic clones exhibited a highly metastatic phenotype, although in most cases the metastatic potential of the hybrids was lower than that of the metastatic parent cells. Very similar results were obtained in athymic nude mice. The metastatic potential of the hybrids was directly correlated with their growth in the subcutis of nude mice. These results indicate that the metastatic capacity of K-1735 cells predominates in somatic cell hybrids between nonmetastatic and metastatic cells. When fusion of nonmetastatic and metastatic cells yields a hybrid with nonmetastatic properties, it may be due to suppression of growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834329

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  The cellular basis of metastasis.

Authors:  P Ruiz; U Günthert
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

2.  Ectopic G-CSF expression in human melanoma lines marks a trans-dominant pathway of tumor progression.

Authors:  S Safarians; S P Rivera; M D Sternlicht; F Naeim; S H Barsky
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

3.  Site-dependent differences in clinical, pathohistological, and molecular parameters in metastatic colon cancer.

Authors:  Christoph Wilmanns; Sandra Steinhauer; Joachim Grossmann; Günther Ruf
Journal:  Int J Biol Sci       Date:  2009-06-26       Impact factor: 6.580

4.  Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones.

Authors:  K L van Golen; S Risin; A Staroselsky; D Berger; M A Tainsky; S Pathak; J E Price
Journal:  Clin Exp Metastasis       Date:  1996-03       Impact factor: 5.150

5.  Expression of the Elm1 gene, a novel gene of the CCN (connective tissue growth factor, Cyr61/Cef10, and neuroblastoma overexpressed gene) family, suppresses In vivo tumor growth and metastasis of K-1735 murine melanoma cells.

Authors:  Y Hashimoto; N Shindo-Okada; M Tani; Y Nagamachi; K Takeuchi; T Shiroishi; H Toma; J Yokota
Journal:  J Exp Med       Date:  1998-02-02       Impact factor: 14.307

Review 6.  Tumor Hybrid Cells: Nature and Biological Significance.

Authors:  Maria S Tretyakova; Ayalur R Subbalakshmi; Maxim E Menyailo; Mohit Kumar Jolly; Evgeny V Denisov
Journal:  Front Cell Dev Biol       Date:  2022-02-15

7.  Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells.

Authors:  K Xie; S Huang; Z Dong; S H Juang; M Gutman; Q W Xie; C Nathan; I J Fidler
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

8.  Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor.

Authors:  Z Dong; J Yoneda; R Kumar; I J Fidler
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.